Cargando…

ANCA Status or Clinical Phenotype — What Counts More?

PURPOSE OF REVIEW: There is ongoing debate concerning the classification of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. That is, whether classification should be based on the serotype (proteinase 3 (PR3)- or myeloperoxidase (MPO)-ANCA) or on the clinical phenotype (granulomatos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Windpessl, Martin, Bettac, Erica L., Gauckler, Philipp, Shin, Jae Il, Geetha, Duvuru, Kronbichler, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Vasculitis (C Dejaco and C Duftner, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081707/ https://www.ncbi.nlm.nih.gov/pubmed/33909191 http://dx.doi.org/10.1007/s11926-021-01002-0

Ejemplares similares

Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?
por: Toyoda, Task, et al.
Publicado: (2022)

The Nasal Microbiome in ANCA-Associated Vasculitis: Picking the Nose for Clues on Disease Pathogenesis
por: Dekkema, G. J., et al.
Publicado: (2021)

Patient Reported Outcomes in Large Vessel Vasculitides
por: Robson, Joanna, et al.
Publicado: (2021)

Blood Biomarkers for Monitoring and Prognosis of Large Vessel Vasculitides
por: Tombetti, Enrico, et al.
Publicado: (2021)

Advances in the Treatment of Behcet’s Disease
por: Alibaz-Oner, Fatma, et al.
Publicado: (2021)

Localized Forms of Vasculitis
por: Martins-Martinho, Joana, et al.
Publicado: (2021)

Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases
por: Lötscher, Fabian, et al.
Publicado: (2022)

Spectrum of Large and Medium Vessel Vasculitis in Adults: Primary Vasculitides, Arthritides, Connective Tissue, and Fibroinflammatory Diseases
por: Seitz, Luca, et al.
Publicado: (2022)

Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023)

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis
por: Palmowski, Andriko, et al.
Publicado: (2020)

Treatment of Giant Cell Arteritis and Takayasu Arteritis—Current and Future
por: Hellmich, B., et al.
Publicado: (2020)

Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel Vasculitides
por: Schäfer, Valentin Sebastian, et al.
Publicado: (2020)

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach
por: Martinez Valenzuela, Laura, et al.
Publicado: (2019)

CSF2-dependent monocyte education in the pathogenesis of ANCA-induced glomerulonephritis
por: Rousselle, Anthony, et al.
Publicado: (2022)

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2019)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
por: King, Catherine, et al.
Publicado: (2017)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)

Diagnostic significance of antineutrophil cytoplasmic antibody (ANCA) titres: a retrospective case-control study
por: Merindol, Julie, et al.
Publicado: (2023)

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
por: Heijl, Caroline, et al.
Publicado: (2017)

ANCA-associated renal vasculitis is associated with rurality but not seasonality or deprivation in a complete national cohort study
por: Aiyegbusi, Oshorenua, et al.
Publicado: (2021)

Prevalence and risk factors of osteonecrosis of the femoral head in patients with ANCA-associated vasculitis: a multicentre cohort study
por: Mimura, Norihiro, et al.
Publicado: (2023)

Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial
por: Romand, Xavier, et al.
Publicado: (2023)

Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry
por: Puéchal, Xavier, et al.
Publicado: (2022)

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism
por: Casal Moura, Marta, et al.
Publicado: (2023)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening
por: Xu, Tingting, et al.
Publicado: (2022)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Schirmer, Jan Henrik, et al.
Publicado: (2023)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
por: Sanchez-Alamo, Beatriz, et al.
Publicado: (2023)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

Seasonal variations in the onset of positive and negative renal ANCA-associated vasculitis in Spain
por: Draibe, Juliana, et al.
Publicado: (2018)

Cardiovascular diseases and their associations with lipid parameters and endothelial dysfunction in giant cell arteritis
por: Jud, Philipp, et al.
Publicado: (2023)

Long delay from symptom onset to first consultation contributes to permanent vision loss in patients with giant cell arteritis: a cohort study
por: Hemmig, Andrea Katharina, et al.
Publicado: (2023)

What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern
por: Gauckler, Philipp, et al.
Publicado: (2021)

Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
por: Izumi, Keisuke, et al.
Publicado: (2015)

Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review
por: Mackie, Sarah Louise, et al.
Publicado: (2015)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vi2rbvmi0is53ddcfdlc0g37t5